Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.1.327

Treatment and Outcomes of Ewing Sarcoma in Turkish Adults: A Single Centre Experience  

Seker, Mehmet Metin (Department of Medical Oncology, Cumhuriyet University Medical Faculty)
Kos, Tugba (Department of Medical Oncology, Manisa State Hospital)
Ozdemir, Nuriye (Department of Medical Oncology, Numune Education and Research Hospital)
Seker, Ayse (Department of Medical Oncology, Mutki State Hospital)
Aksoy, Sercan (Department of Medical Oncology, Hacettepe University Cancer Institute)
Uncu, Dogan (Department of Medical Oncology, Numune Education and Research Hospital)
Zengin, Nurullah (Department of Medical Oncology, Numune Education and Research Hospital)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.1, 2014 , pp. 327-330 More about this Journal
Abstract
Background: Ewing sarcoma is a small round cell tumor arising from soft tissue and bone that predominantly affects children and adolescents. The most unfavorable prognostic factor is the presence of distant metastasis at the time of diagnosis. Materials and Methods: The records of 26 Ewing sarcoma patients (14 male, 12 female) were re-evaluated retrospectively. Results: The median age was 26.5 (19-42) years. Eight patients (31%) showed a primary tumor in their extremities, 8 (31%) in the thorax, 4 (15%) at the vertebra, 4 (15%) in the head and neck, and 2 (8%) in the abdomen. Five patients (19%) had distant metastasis at diagnosis. The median progression-free survival was 72 months and 10 months in localized and metastatic disease, respectively (p=0.005). The overall survival rate was 19 months in metastatic disease, and the 5-year overall survival rate was 64% in localized disease (p=0.006). Patients who had localized disease in the extremities and were under age 30 had a favorable prognosis. Conclusions: Although Ewing sarcoma is a tumor affecting children and adolescents, it may be seen in adults, where the prognosis is generally worse. Although it is a highly malignant tumor, it is possible to achieve improved survival with combined modality treatments.
Keywords
Adult cases; Ewing sarcoma; prognosis; Turkey;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Baldini, EH, Demetri GD, Fletcher CD, et al (1999). Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome. Ann Surg, 230, 79-86.   DOI
2 Barbieri E, Emiliani E, Zini G, et al (1990). Combined therapy of localized Ewing's sarcoma of bone: analysis of results in 100 patients. Int J Radiat Oncol Biol Phys, 19, 1165-70.   DOI
3 Collier AB, 3rd Simpson L, Monteleone P (2011). Cutaneous Ewing sarcoma: report of 2 cases and literature review of presentation, treatment, and outcome of 76 other reported cases. J Pediatr Hematol Oncol, 33, 631-4.   DOI   ScienceOn
4 Cotterill SJ, Ahrens S, Paulussen M, et al (2000). Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol, 18, 3108-14.
5 Saeter G (2007). Ewing's sarcoma of bone: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 18, 79-80.
6 Kushner BH, Meyers PA (2001). How effective is dose-intensive/ myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol, 19, 870-80.
7 Obata H, Ueda T, Kawai A, et al (2007). Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group cooperative study. Cancer, 109, 767-75.   DOI   ScienceOn
8 Oberlin O, Deley MC, Bui BN, et al (2001). Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer, 85, 1646-54.   DOI   ScienceOn
9 Schwartz GK, Tap WD, Qin LX, et al (2013). Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol, 14 371-82.   DOI   ScienceOn
10 Scurr M, Judson I (2006). How to treat the Ewing's family of sarcomas in adult patients. Oncologist, 11, 65-72.   DOI   ScienceOn
11 Shannon Orr W, Denbo JW, Billups CA, et al (2012). Analysis of prognostic factors in extraosseous Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital experience. Ann Surg Oncol, 19, 3816-22.   DOI
12 Grier HE, Krailo MD, Tarbell NJ, et al (2003). Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med, 348, 694-701.   DOI   ScienceOn
13 Gupta AA, Pappo A, Saunders N, et al (2010). Clinical outcome of children and adults with localized Ewing sarcoma: impact of chemotherapy dose and timing of local therapy. Cancer, 116, 3189-94.   DOI   ScienceOn
14 Fizazi K, Dohollou N, Blay JY, et al (1998). Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol, 16, 3736-43.
15 Granowetter L, Womer R, Devidas M, et al (2009). Doseintensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol, 27, 2536-41.   DOI   ScienceOn
16 Iwamoto Y (2007). Diagnosis and treatment of Ewing's sarcoma. Jpn J Clin Oncol, 37, 79-89.   DOI   ScienceOn
17 Juergens H, Daw NC, Geoerger B, et al (2011). Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol, 29, 4534-40.   DOI
18 Jurgens, H, U Dirksen (2011). Ewing sarcoma treatment. Eur J Cancer, 47, 366-7.
19 Kolb EA, Kushner BH, Gorlick R, et al (2003). Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 21, 3423-30.   DOI   ScienceOn
20 Jurgens H, Exner U (1988). Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer, 61, 23-32.   DOI
21 Applebaum MA, Worch J, Matthay KK, et al (2011). Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. Cancer, 117, 3027-32.   DOI   ScienceOn
22 Bacci G, Ferrari S, Comandone A, et al (2000). Neoadjuvant chemotherapy for Ewing's sarcoma of bone in patients older than thirty-nine years. Acta Oncol, 39, 111-6.   DOI
23 Tap WD, Demetri G, Barnette P, et al (2012). Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol, 30, 1849-56.   DOI   ScienceOn
24 van Doorninck JA, Ji L, Schaub B, et al (2010). Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol, 28, 1989-94.   DOI   ScienceOn
25 Bacci G, Dallari D, McDonald D, et al (1989). Neoadjuvant chemotherapy for localized Ewing's sarcoma of the extremities: preliminary results of a protocol which uses surgery (alone or followed by radiotherapy) for local control. Tumori, 75, 456-62.
26 Balamuth N J, Womer RB (2010). Ewing's sarcoma. Lancet Oncol, 11, 184-92.   DOI   ScienceOn
27 Subbiah V, Anderson P, Lazar AJ, et al (2009). Ewing's sarcoma: standard and experimental treatment options. Curr Treat Options Oncol, 10, 126-40.   DOI   ScienceOn